Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients. The ...

It is preparing to enter Phase 2 trials in patients who received the ADC cancer drug 'Enhertu' (ingredient name trastuzumab ... It also acquired two antibodies for treating solid tumors such as lung ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

An international study found that air pollution leads to more cancer-related genetic changes than secondhand smoke.

Exposure to air pollution, other contaminants and traditional herbal medicines may be contributing to the development of lung ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

Research from the NIH’s National Cancer Institute, an agency beleaguered by funding cuts and censorship, finds that ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Air pollution and herbal medicines could be behind lung cancer in non-smokers, study finds - Researchers say never-smokers ...